• Title/Summary/Keyword: CNKI

Search Result 534, Processing Time 0.021 seconds

A Literature Study on Acupuncture for Cerebral Palsy -Based on the Current Traditional Chinese Medical Journals- (뇌성마비의 침자(鍼刺) 치료에 대한 문헌적 고찰 -최근 중의잡지를 중심으로-)

  • Ha, Su-Yun;Min, Sang-Yeon;Kim, Jang-Hyun
    • The Journal of Pediatrics of Korean Medicine
    • /
    • v.23 no.1
    • /
    • pp.205-228
    • /
    • 2009
  • Objectives The purpose of this study is to investigate the current acupuncture therapy of cerebral palsy. Methods We investigated the Chinese clinical papers which were published in the last 10 years(from 1999 to 2008). We found these papers from the oriental medical library in university and we also used the China National Knowledge Infrastructure(CNKI) through the internet and selected 32 papers for analyzing. Results Most papers were described the effect of acupuncture or acupoint-injection. This is more effective way to treat than the general rehabilitation treatment such as the physical therapy, the occupational therapy, and the speech therapy. Acupuncture or acupoint-injection has overall $80{\sim}100%$ of rehabilitation rate. The younger the children were, the longer the treatment period was, and the more successful in treatment. The acupuncture was often used with the general acupuncture and scalp acupuncture. Commonly used major acupuncture points were sishencong(四神聰), bohui(百會), zusanli(足三里), yundongqu(運動區), pinghengqu(平衡區), quchi(曲池), and sanyinjiao(三陰交). Commonly used main meridian pathways were bladder, governor vessel, gallbladder, large intestine, stomach, small intestine meridian. Head is the common site for acupuncture. The main acupoint-injection points were zusanli(足三里), dazhui(大椎), shenshu(腎兪), yamen(啞門), neiguan(內關), and fengchi(風池). For the injection, brain activator, ganglioside M1, cerebroprotein hydrolysate, cytidine diphosphate choline, Vit B1, Vit B12, the salviae root, the safflower were commonly used. Conclusions Acupuncture and acupoint-injection have been shown as an effective treatment on cerebral palsy. The acupuncture was used often the general acupuncture and scalp acupuncture all together. Commonly used main acupuncture points were sishencong, bohui, zusanli, yundongqu, pinghengqu, quchi, sanyinjiao.

  • PDF

A Literary Review on Early Treatment of Cerebral Palsy - Centered on the Chinese Medical Journal - (뇌성마비의 조기치료에 관한 문헌적 고찰 - 최근 중의 잡지 중심으로 -)

  • Gok, Su-Yeong;Lee, Seung-Yeon;Lyu, Sun-Ae
    • The Journal of Pediatrics of Korean Medicine
    • /
    • v.22 no.3
    • /
    • pp.35-62
    • /
    • 2008
  • Objectives : This study has been carried out to look into the methods of early treatment of cerebral palsy and the treatment effect by ages. Methods : The fifteen theses dealing with treatment effects by ages were analyzed, which were selected from the 121 theses retrieved out of the wu-ruan(五軟), wu-chi(五遲), wu-ying(五硬), naotan(腦癱), naoxing-tanhuan(腦性癱癱), during the period between the January 2004 to August 2008 by using the China Academic Journal(CAJ) of China National Knowledge Infrastructure(CNKI). Results : 1. Among the study objects in the 15 theses, it was identified that there were 1.97 times more boys with cerebral palsy than that of girls, and it appeared that there was no significant relationship between gender and the treatment. 2. The early treatment referred to the treatment which was carried out based on the early diagnosis within 6 months to one year after the birth. This is the time when the adaptability and plasticity of the brain are high, and it was found out that the treatment effective as babies are young. 3. For the treatment of cerebral palsy, the combination of Traditional Chinese and Western Medicine Therapy was more frequently used than the exclusive Chinese medical treatment method, and it was more effective. Especially in the case, the Chinese medical treatment was focused on the acupuncture and the Tuina Massage. Conclusions : 1. For the treatment of cerebral palsy, when the age between one and two years old was established as the standard. The younger the babies were, the higher treatment effects were obtained. 2. It appeared that the early treatment of oriental medicine had relatively excellent effects on cerebral palsy, but it turned out that we needed more studies for accurate results.

  • PDF

Mahaenggamsuktang for treating Mycoplasma pneumonia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials (RCTs) (마행감석탕의 소아 마이코플라즈마 폐렴 치료에 대한 체계적 문헌 고찰 및 메타분석)

  • Lee, Yoo Been;Jeong, Aram
    • The Journal of Pediatrics of Korean Medicine
    • /
    • v.34 no.2
    • /
    • pp.90-108
    • /
    • 2020
  • Objectives The purpose of this study is to evaluate efficacy and safety of Mahaenggamsuktang for treating mycoplasma pneumonia in children based on the randomized controlled trials (RCTs). Methods Literatures were searched from OASIS, KISS, NDSL, CNKI, Cochrane, Embase and Pubmed, and the search was conducted on January 29, 2020. Only RCTs published since 2000 were included. Trials comparing Mahaenggamsuktang combined with antibiotics or antibiotics treatment alone for the treatment of mycoplasma pneumonia in children were included. Results 17 trials, including 2,241 participants with mycoplasma pneumonia were included in this review. As a result of the meta-analysis, total effective rate of combination of Mahaggamsuktang and antibiotics was 1.24 times higher than that of the antibiotics alone, which was statistically significant. Symptoms with fever, lung sounds, cough, chest X-ray lesion findings, wheezing were also significantly reduced in the treatment group with Mahaenggamseoktang and antibiotics. Also, Serum CRP level was significantly lower with combination treatment. The incidence of adverse reactions was lower in the treatment group with Mahaenggamseoktang and antibiotics, but it was not statistically significant. Conclusions As a result of meta-analysis, combination treatment of Mahaenggamseoktang and antibiotics seems significantly effective for the treatment of mycoplasma pneumonia in children. In order to have a higher level of evidence for efficacy and safety of Mahaenggamsuktang in treating mycoplasma pneumonia, additional RCTs with good qualities are required.

The CCND1 G870A Gene Polymorphism and Leukemia or Non-Hodgkin Lymphoma Risk: a Meta-analysis

  • Qin, Ling-Yan;Zhao, Li-Gang;Chen, Xu;Yang, Zheng;Mo, Wu-Ning
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.16
    • /
    • pp.6923-6928
    • /
    • 2014
  • In recent years, mounting evidence has indicated that the CCND1 G870A gene polymorphism, which impacts the mitotic cell cycle, may influence leukemia or non-Hodgkin lymphoma risk. Unfortunately, the previous results were inconsistent. Therefore, a meta-analysis was performed to obtain a more precise estimation of any association. We conducted a search in PubMed, Embase and CNKI covering all published papers up to March, 2014. A total of 9 publications including 10 case-control studies met the inclusion criteria. Odds ratios (ORs) and their 95% confidence intervals (95%CIs) were applied to assess association. The pooled ORs showed significant association in non-Hodgkin lymphoma (comparison A vs G: OR= 1.114, 95%CI=1.053-1.179, p=0.000; homozygote comparison AA vs GG: OR=1.245, 95%CI=1.110-1.396, p=0.000; heterozygote comparison AG vs GG: OR=1.095, 95%CI=1.000-1.199, p=0.05; dominant model AA/GA vs GG: OR=1.137, 95%CI=1.043-1.239, p=0.003; and recessive model AA vs GA/GG: OR=1.177, 95%CI=1.066-1.301, p=0.001). However, there was no association between the CCND1 G870A polymorphism and leukemia risk. In conclusion, the CCND1 G870A polymorphism may increase risk of non-Hodgkin lymphoma, but not leukemia. However, more primary large scale and well-designed studies are still required to evaluate the interaction of CCND1 G870A polymorphism with leukemia and non-Hodgkin lymphoma risk.

Anti-Diabetic Medications Do Not Influence Risk of Lung Cancer in Patients with Diabetes Mellitus: a Systematic Review and Meta-analysis

  • Nie, Shu-Ping;Chen, Hui;Zhuang, Mao-Qiang;Lu, Ming
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.16
    • /
    • pp.6863-6869
    • /
    • 2014
  • Objectives: Several preclinical and observational studies have shown that anti-diabetic medications (ADMs) may modify the risk of lung cancer. We performed a systematic review and meta-analysis evaluating the effect of metformin, sulfonylureas (SUs), thiazolidinediones (TZDs), and insulin on the risk of lung cancer in patients with diabetes mellitus (DM). Materials and Methods: We conducted a systematic search of Pubmed and Web of Science, up to August 20, 2013. We also searched the Conference Proceedings Citation Index (CPCI) and China National Knowledge Infrastructure (CNKI) for abstracts from major meetings. Fixed or random effect pooled measures were selected based on heterogeneity among studies, which was evaluated using Q test and the I2 of Higgins and Thompson. Meta-regression was used to explore the sources of between-study heterogeneity. Publication bias was analyzed by Begg's funnel plot and Egger's regression test. Associations were assessed by odds ratios (ORs) with 95% confidence intervals (CIs). Results: A total of 15 studies (11 cohort, 4 case-control) were included in this meta-analysis. In observational studies no significant association between metformin (n=11 studies; adjusted OR=0.99, 95%CI: 0.87-1.12), SUs (n=5 studies; adjusted OR=0.98, 95%CI: 0.79-1.22), or TZDs (n=7 studies; adjusted OR=0.92, 95%CI: 0.75-1.13), insulin (n=6 studies; adjusted OR=1.13, 95%CI: 0.79-1.62) use and risk of developing lung cancer was noted. There was considerable inherent heterogeneity between studies not explained by study design, setting, or location. Conclusions: Meta-analysis of existing studies does not support a protective or harmful association between ADMs use and risk of lung cancer in patients with DM. There was considerable heterogeneity across studies, and future, well-designed, prospective studies would be required for better understanding of any association.

Association between the TP53BP1 rs2602141 A/C Polymorphism and Cancer Risk: A Systematic Review and Meta-Analysis

  • Liu, Lei;Zhang, Dong;Jiao, Jing-Hua;Wang, Yu;Wu, Jing-Yang;Huang, De-Sheng
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.6
    • /
    • pp.2917-2922
    • /
    • 2014
  • Background: The p53-binding protein 1 (TP53BP1) gene may be involved in the development of cancer through disrupting DNA repair. However, investigation of associations between TP53BP1 rs2602141 A/C polymorphism and cancer have yielded contradictory and inconclusive outcomes. We therefore performed a meta-analysis to evaluate the association between the TP53BP1 rs2602141 A/C polymorphism and cancer susceptibility. Materials and Methods: Published literature from PubMed, Medline, the Cochrane Library, EMbase, Web of Science, Google (scholar), CBMDisc, Chongqing VIP database, and CNKI database were retrieved. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed or random-effects models. Publication bias was estimated using funnel plots, Begg's and Egger's test. Results: A total of seven studies (3,018 cases and 5,548 controls) were included in the meta-analysis. Our results showed that the genotype distribution of TP53BP1 rs2602141 A/C was not associated with cancer risk overall. However, on subgroup analysis, we found that TP53BP1 rs2602141 A/C was associated with cancer risk within an allele model (A vs C, OR=1.14, 95%CI: 1.01-1.29) and a codominant model (AA vs CC, OR=1.36, 95%CI: 1.06-1.74) in Asians rather than in Caucasians. Subgroup analysis by cancer type, genotype, and with or without adjustment for controls showed no significant association. Conclusions: The findings suggested an association between rs2602141 A/C polymorphism in TP53BP1 gene and increased risk of cancer in Asians.

Vitamin D Receptor BsmI Polymorphism and Colorectal Cancer Risk: an Updated Analysis

  • Yu, Kun;Yang, Jing;Jiang, Yan;Song, Run;Lu, Qing
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.12
    • /
    • pp.4801-4807
    • /
    • 2014
  • Background: Previous studies have investigated the association between the vitamin D receptor (VDR) BsmI polymorphism and colorectal cancer (CRC) susceptibility, but the results were conflicting. The aim of this study is to quantitatively summarize the relationship between this polymorphism and CRC risk. Materials and Methods: Two investigators independently searched the Medline, Embase, China National Knowledge Infrastructure (CNKI) and Chinese Biomedicine databases for studies published before November 2013. Summary odds ratios (ORs) and 95% confidence intervals (95%CIs) for VDR BsmI polymorphism and CRC were calculated in a fixed-effects model (the Mantel-Haenszel method) and a random-effects model (the DerSimonian and Laird method) when appropriate. Results: This meta-analysis included 14 case-control studies, which included 10,822 CRC cases and 11,779 controls. Overall, the variant genotype (BB) of the BsmI was associated with a lower CRC risk when compared with the wild-type bb homozygote (OR=0.66, 95%CI: 0.49-0.88). Similarly, a decreased CRC risk was also found in the dominant and recessive models. When stratifying for ethnicity, source of controls, and study sample size, associations were observed among Caucasians, population-based studies and studies with large study sample size (>1000 subjects). Limiting the analysis to the studies within Hardy-Weinberg equilibrium, the results were persistent and robust. No publication bias was found in the present study. Conclusions: This updated meta-analysis suggests that the VDR BsmI polymorphism may be associated with a moderate protective effect against CRC.

Lack of Association of the Cyclooxygenase-2 Gene 8473T>C Polymorphism with Breast Cancer Risk: a Meta-analysis

  • Yang, Xi;Zhao, Fen;Li, Yue-Hua;Huang, Min;Huang, Ying;Yi, Cheng
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.22
    • /
    • pp.9693-9698
    • /
    • 2014
  • Background: Associations between the 8473T>C polymorphism (rs5275) in the cyclooxygenase-2 (COX-2) gene and breast cancer (BC) risk are still inconclusive and ambiguous. The aim of this meta-analysis was to comprehensively estimate the genetic risk of 8473T>C polymorphism in the COX-2 gene for BC. Materials and Methods: We searched PubMed, Web of Science, Medline, Chinese biomedical (CBM), Weipu, China national knowledge infrastructure (CNKI), and Wanfang databases, covering all publications (last search was updated on Aug 17, 2014). Statistical analyses were performed using Revman 5.3 and STATA 10.0 software. Results: A total of 6,720 cases and 9,794 controls in 12 studies were included in this study. The results indicated no significant associations between the 8473T>C polymorphism of the COX-2 gene and BC risk for the CC+TC vs TT model (pooled odds ratio (OR)=0.97, 95% confidence interval (CI)=0.90-1.03, and p=0.29). On subgroup analysis, we also found that subdivision on ethnicity among Caucasians, Asians and others also revealed no relationship with BC susceptibility. With the study design (CC+TC vs TT), no significant associations were found in either population-based case-control studies (PCC), or hospital-based case-control studies (HCC). Conclusions: This present meta-analysis suggests that the 8473T>C polymorphism in the COX-2 gene is not a conspicuous low-penetrant risk factor for developing BC.

Meta-analysis of Excision Repair Cross-complementation Group 1 (ERCC1) Association with Response to Platinum-based Chemotherapy in Ovarian Cancer

  • Li, Feng-Ying;Ren, Xiao-Bin;Xie, Xin-You;Zhang, Jun
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.14 no.12
    • /
    • pp.7203-7206
    • /
    • 2013
  • Recent studies suggested that the ovarian cancers with negative excision repair cross-complementation group 1 enzyme (ERCC1) expression have a better response to platinum-based chemotherapy than those with positive ERCC1 expression. The objective of this study was to evaluate whether ERCC1 expression is associated with response to platinum-based chemotherapy in ovarian cancers. MEDLINE, PubMed, Web of Science and CNKI databases were used for searching studies relating to ERCC1 protein expression and response to platinum-based chemotherapy in ovarian cancers. Statistical analysis was based on the method for a fixed effects meta-analysis. Pooled odds ratios (ORs) with 95% confidence intervals for ERCC1 protein expression and response to platinum-based chemotherapy were generated. Publication bias was investigated with Begg's test. Five studies involving 306 patients with ovarian cancer were included. Compared to patients with positive ERCC1 expression, those with negative ERCC1 expression had a better response to platinum-based chemotherapy. The pooled OR was 5.264 (95% CI: 2.928-9.464, P < 0.001) and publication bias was not found (P = 0.904). The result was similar in both in Asians and Caucasians (P < 0.001 and P = 0.028, respectively). ERCC1 protein expression status is significantly associated with response to platinum-based chemotherapy in ovarian cancers.

Common Variants in the PALB2 Gene Confer Susceptibility to Breast Cancer: a Meta-analysis

  • Zhang, Yi-Xia;Wang, Xue-Mei;Kang, Shu;Li, Xiang;Geng, Jing
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.14 no.12
    • /
    • pp.7149-7154
    • /
    • 2013
  • Objective: Increasing scientific evidence suggests that common variants in the PALB2 gene may confer susceptibility to breast cancer, but many studies have yielded inconclusive results. This meta-analysis aimed to derive a more precise estimation of the relationship between PALB2 genetic variants and breast cancer risk. Methods: An extensive literary search for relevant studies was conducted in PubMed, Embase, Web of Science, Cochrane Library, CISCOM, CINAHL, Google Scholar, CNKI and CBM databases from their inception through September 1st, 2013. A meta-analysis was performed using the STATA 12.0 software and crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Results: Six case-control studies were included with a total of 4,499 breast cancer cases and 6,369 healthy controls. Our meta-analysis reveals that PALB2 genetic variants may increase the risk of breast cancer (allele model: OR>1.36, 95%CI: 1.20~1.52, P < 0.001; dominant model: OR>1.64, 95%CI: 1.42~1.91, P < 0.001; respectively). Subgroup analyses by ethnicity indicated PALB2 genetic variants were associated with an increased risk of breast cancer among both Caucasian and Asian populations (all P < 0.05). No publication bias was detected in this meta-analysis (all P > 0.05). Conclusion: The current meta-analysis indicates that PALB2 genetic variants may increase the risk of breast cancer. Thus, detection of PALB2 genetic variants may be a promising biomarker approach.